- Home
- / Tetraphase Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Tetraphase Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$7.4 M
FY, 2019
CreditSafe Score
?
Score changed on Apr 27, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 10.5M | 9.1M | 11.7M | 5.1M | 9.7M | 18.9M | 7.4M |
| Revenue growth, % | -50.2% | 28.4% | -56.0% | ||||
| General and administrative expense | 7.2M | 12.9M | 20.9M | 19.2M | 23.7M | 37.1M | 49.0M |
| Operating expense total | 38.7M | 74.9M | 94.7M | 83.0M | 125.4M | 92.0M | 71.8M |
| EBIT | (28.2M) | (65.8M) | (83.0M) | (77.8M) | (115.7M) | (73.3M) | (67.5M) |
| EBIT margin, % | -268.8% | -722.9% | -710.2% | -1512.7% | -1197.1% | -387.6% | -915.6% |
| Interest income | 10.0K | 17.0K | 42.0K | 350.0K | 1.7M | 1.3M | |
| Interest expense | 1.4M | 976.0K | 191.0K | 350.0K | 963.0K | ||
| Pre tax profit | (83.2K) | (77.5M) | (114.8M) | (72.2M) | (70.1M) | ||
| Net Income | (29.6M) | (66.7M) | (83.2M) | (77.5M) | (114.8M) | (72.2M) | (70.1M) |